Abstract
Currently, the treatment options for the erectile dysfunction (ED) related to radical prostatectomy (RP) include the phosphodiesterase-5 inhibitor (PDE5i) as first-line treatment, then intracavernous injections, and penile implants. This issue stills representing the main and frequent adverse effect following RP despite the attempts in performing nerve-sparing procedures and the establishment of the robotic platform.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
